Podcasts about cancer therapies

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, interviews Dr. Brent Sear, director of the Clinical Pharmacology Shared Resource at KU Cancer Center. Brent shares his unique career journey into clinical pharmacology, the role of clinical pharmacology in advancing cancer therapies, and the critical work his team does in guiding clinical trials and personalizing cancer treatment. They also discuss emerging technologies and their potential impact on the future of cancer research. Tune in to learn more about the intricate processes that ensure safe and effective cancer therapies. 00:00 Introduction to the Podcast and Guest 01:06 Brent Sear's Journey into Cancer Research 03:21 Understanding Clinical Pharmacology 04:54 The Role of Clinical Pharmacology Shared Resource 06:40 Importance of Precise Measurement in Cancer Treatment 08:40 Collaborative Projects and Scientific Insights 09:55 Advice for Aspiring Researchers 11:52 Future of Clinical Pharmacology in Cancer Research 13:33 Conclusion and Farewell Links from this Episode: ·       Learn more about the Clinical Pharmacology Shared Resource at KU Cancer Center ·       Learn about Brent Sear, director of the Clinical Pharmacology Shared Resource ·       Learn about Shared Resources and Core Facilities at KU Cancer Center To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.

After 20+ years treating cancer patients, Dr. Christy Kesslering started asking a question her colleagues weren't asking: why are so many of my breast cancer patients metabolically sick — even when they're not obese?That question changed everything.Dr. Kesslering is a classically-trained radiation oncologist, metabolic health practitioner, and terrain theorist. She spent two decades practicing oncology in the Chicagoland area before transitioning to focus full-time on what she believes is the missing piece in cancer care: mitochondrial health, and metabolic dysfunction. She now works with cancer patients and chronic disease clients through a telehealth practice built on comprehensive lab work, real-food nutrition, and terrain-based principles.Questions Answered in This Episode:What is mitochondrial dysfunction and how does it relate to cancer?Are processed foods, seed oils, and glyphosate implicated in rising cancer rates?Can fasting or ketogenic diets reduce chemotherapy side effects?What's the difference between cachexia and healthy fat loss in cancer patients?How do you identify which foods are problematic for your body specifically?What does Dr. Kesslering believe has the biggest impact on cancer outcomes?A rare look at what happens when a passionate physician follows the data wherever it leads — and why she believes the future of cancer care starts with metabolism.Big thanks to our sponsors:✅Genova Connect – Get 15% off any test kit with code METABOLICLINK here!✅ Fatty15 – Get 15% off a 90-day Starter Kit with code METABOLICLINK here.✅ ZocDoc - Find and instantly book a top-rated doctor here.In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: Instagram Facebook YouTube LinkedIn Please keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

Commentary by Dr. Peter van der Meer.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful events and breakthroughs that are shaping patient care and drug development.The U.S. Food and Drug Administration recently granted early approval for a combination therapy using Padcev and Keytruda for the perioperative treatment of bladder cancer, a decision made months ahead of schedule. This approval represents a significant advancement in the therapeutic landscape for this type of cancer, offering new hope to patients who have had limited treatment options. The combination of these two therapies underscores the growing trend of integrating multiple mechanisms of action to tackle complex diseases like cancer more effectively. It also highlights the potential of combination therapies to provide enhanced clinical benefits by leveraging different therapeutic targets.In another notable development, Merck's partner Kelun announced successful Phase 3 trial results for an antibody-drug conjugate combined with Keytruda in treating PD-L1-positive non-small cell lung cancer (NSCLC). The trial results demonstrated statistically significant improvements in progression-free survival compared to Keytruda alone. This finding reinforces the expanding role of antibody-drug conjugates in oncology and emphasizes the importance of biomarker-driven therapies in personalizing cancer treatment. These advancements reflect a broader industry shift towards precision medicine, which aims to improve patient outcomes by tailoring treatments based on individual patient profiles.Meanwhile, Novo Nordisk experienced setbacks as its shares fell nearly 9% following two unsuccessful Phase 3 trials of semaglutide for Alzheimer's disease. Despite these disappointing results, this outcome highlights the persistent challenges and complexities inherent in developing therapies for neurodegenerative diseases—areas where unmet needs remain substantial. The market's reaction reflects investor sensitivity to clinical trial outcomes, particularly in high-stakes areas like Alzheimer's where breakthroughs are eagerly anticipated.Switching gears to AstraZeneca, the company is making a strategic move by expanding its manufacturing capabilities with a $2 billion investment in Maryland. This expansion reflects an ongoing trend among pharmaceutical companies to enhance their production infrastructure, driven by increasing demand for biologics and complex therapeutics. Such investments are crucial for supporting large-scale production needs and ensuring robust supply chains that are essential for meeting global health demands.In regulatory news, a collective letter from biotech CEOs addressed to FDA director Marty Makary has raised concerns about regulatory stability in the U.S., with 82% of biopharma respondents expressing apprehension over the FDA's ability to function predictably. This plea underscores how regulatory volatility can hinder innovation and emphasizes the importance of consistent policies that support long-term research and development efforts.In clinical trial updates, Bayer's oral FXIa inhibitor asundexian has shown promise in reducing stroke risk during Phase 3 trials. These findings revive interest in FXIa inhibitors as potentially blockbuster drugs after previous setbacks in this class. This development illustrates ongoing efforts to identify novel anticoagulant therapies that balance efficacy and safety, offering new hope for improved therapeutic options.Now turning our attention to Johnson & Johnson's recent setback with their anti-tau antibody posdinemab in a phase 2 trial targeting Alzheimer's disease. The trial was unable to demonstrate a significant slowing of clinical decline, leading JSupport the show

Guest: Jun-ichi Abe, MD, PhD Cancer therapies can trigger both acute and chronic vascular effects, from treatment-induced hypertension to long-term atherosclerotic changes. Learn more as Dr. Jun-ichi Abe shares insights from his presentation at the 2025 American Heart Association Scientific Sessions. Dr. Abe is a Professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center in Houston.

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

In today's episode, we are joined by Professor Stephen Maher, an expert in translational oncology and radiation research at Trinity College Dublin, where he also serves as the Director of Postgraduate Studies for the School of Medicine. Stephen's work focuses on understanding why some cancers respond to treatment while others resist it — particularly in relation to chemotherapy and radiotherapy. His research explores how factors like microRNAs, the DNA damage response, and tumor hypoxia influence treatment sensitivity, with a strong emphasis on oesophageal and pancreatic cancers. Hit play to explore: The future of anti-cancer therapeutics. The ways that radiation research is evolving. Why translational oncology is so important for improving patient outcomes. After completing his Ph.D. in Oncology at RCSI and a fellowship at the National Cancer Institute in Maryland, Stephen has built a career dedicated to bridging lab-based discovery with patient-focused care. He leads national and international collaborations in cancer biology and has helped develop cutting-edge radiotherapy and hypoxia research cores at Trinity's Translational Medicine Institute. Click here to learn more about Stephen and his important work!

What if the cancer treatment that works best is the one pharmaceutical companies can't profit from? What if one of the cancer treatments that works best is the one the pharmaceutical companies can't profit from?!Dr. Katie sits down again with Professor Thomas Seyfried to explore why the medical system resists alternative approaches to a disease that claims over 1,700 lives daily in the U.S., and what's actually driving cancer at the cellular level. They reveal a specific therapeutic strategy that targets both fuels cancer cells depend on to survive.Dr. Seyfried explains how cancer isn't the genetic lottery you've been led to believe, it's a metabolic condition with a metabolic solution. You'll learn why your body's normal cells thrive on completely different fuel than cancer cells do, and how a compound called DON (a glutamine antagonist) combined with therapeutic ketosis creates conditions where healthy cells flourish while cancer cells can't survive. Chapters:00:13:25 – Starving the Tumor00:16:22 – The Banned Cancer Drug00:21:03 – Beyond the Keto Diet00:32:00 – Why Healing Threatens the ‘System'00:37:15 – The Genetic MythDr. Katie and Dr. Seyfried discuss the practical challenges patients face when trying to find providers who understand this science, why measuring your glucose-ketone index matters more than following any specific meal plan.Dr. Seyfried's research team is seeing remarkable outcomes in advanced cases that conventional medicine has given up on, and he shares exactly what that approach looks like.Listen and learn why the paradigm shift in cancer management isn't just coming, it's already here, waiting for the rest of the world to catch up.Dr. Seyfried: https://www.bc.edu/bc-web/schools/morrissey/departments/biology/people/faculty-directory/thomas-seyfried.htmlAccess the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Work with Dr. Katie: www.katiedeming.com 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Email: INFO@KATIEDEMING.COM Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast Watch on Youtube: https://youtube.com/playlist?list=PL5LplU70TE9i01tW_7Tozi8b6X6rGBKA2&si=ZXLy5PjM7daD6AV5 DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

In this episode, we talk with Dr. Sharon about the complex intersection of oncology and autoimmunity through the lens of immune checkpoint inhibitors (ICIs)—therapies that have transformed cancer care but can also unleash immune-related adverse events (irAEs). Dr. Elad explains how ICIs work, why they can trigger autoimmune-like toxicities, and what distinguishes rheumatologic irAEs from classic autoimmune diseases. We explore the mechanistic overlaps between cancer immunotherapy and autoimmunity, the ethical and clinical dilemmas of balancing immune suppression with cancer control, and emerging biomarkers that may predict risk. Dr. Sharon also reflects on his career journey—from leading drug development efforts at the National Cancer Institute to returning to academia—and shares insights on collaboration, innovation, and the evolving partnership between oncologists and rheumatologists in managing these challenging conditions. 

Dr. Bahar Mansoori explores how musculoskeletal complications from radiation therapy and immunotherapy can mimic metastatic disease and pose diagnostic challenges. She discusses key imaging patterns, pitfalls, and strategies radiologists can use to improve accuracy and patient care.   Musculoskeletal Complications of RadiationTherapy and Immunotherapy. Azhideh and Haseli et al. RadioGraphics 2025; 45(10):e250014. 

Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive's Stephen Gunnion about first-in-human data for the company's targeted hyperthermia therapy (THT), showing significant tumor response in patients with late-stage melanoma. The early feasibility study involved ten patients who had not responded to standard immunotherapy. Regan said, “We were able to get a response in eight out of ten of them, of which six were complete responses.” Biopsies conducted within two weeks confirmed that the treated tumors no longer contained melanoma cells. THT uses nanoparticles injected into tumors and activated by a near-infrared laser. The laser energy creates heat at 45°C, selectively killing cancer cells without harming healthy tissue. The process also stimulates the immune system, which Regan said was a critical component: “We're really helping to fire up the immune system to fight the cancer on its own.” Sona now plans to move into a Canadian clinical trial, pending Health Canada approval. Regan emphasized that these results could extend beyond melanoma, potentially benefiting other solid tumors resistant to immunotherapy. Investors can expect updates on histological data analysis and direction for broader clinical applications. Sona has already submitted an application to Health Canada and hopes to engage with the regulator soon. #SonaNanotech #CancerTreatment #TargetedHyperthermia #Melanoma #BiotechNews #Immunotherapy #ClinicalTrials #Oncology #MedicalInnovation #HealthcareTech

Although initial clinical trials of tamoxifen as a treatment of breast cancer were positive, Imperial Chemical Industries (ICI) did not believe this market would be commercially viable. The company had hoped for a contraceptive pill – tamoxifen didn't work for that – not a cancer treatment. In 1972 the higher-ups at ICI decided to cancel the research.‍But Dora Richardson, the chemist who had originally synthesized the compound, and her boss, Arthur Walpole, were convinced they were on to something important, something that could save lives. They continued the research in secret. Tamoxifen was eventually launched in 1973 and went on to become a global success, saving hundreds of thousands of lives. Dora Richardson's role in its development, however, was overshadowed by her a male colleague and all but forgotten.This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez. Learn about your ad choices: dovetail.prx.org/ad-choices

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

In the early 1960s, Dr. Dora Richardson synthesized a chemical compound that became one of the most important drugs to treat breast cancer: tamoxifen. Although her name is on the original patent, her contributions have been lost to history.In the first episode of this two-part podcast, Katie Couric introduces us to Dora's story, and we show how Lost Women of Science producer Marcy Thompson tracked down Dora's firsthand account of the history of the drug's development. This document, lost for decades, tells the story of how the compound was made and how Imperial Chemical Industries, where Richardson worked, almost terminated the project because the company was hoping to produce a contraceptive, not a cancer therapy.This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez. Learn about your ad choices: dovetail.prx.org/ad-choices

"It is not everyone who will require radiation treatment for a diagnosis of cancer" - Dr. Stephen Kpatsi [Clinical/Radiation Oncologist]

In this Episode, Radiation Oncologist, Dr. Stephen Kpatsi helps us understand systemic and localized treatment approaches to cancer through chemotherapy and radiation therapy, their mechanisms of action, side effects, and how they complement other treatment modalities.

"The more cancer grows, the more it wants to move further away from where it wants to go" - Dr. Elliott Arko-Boham

In this episode, we explore surgical interventions as a primary treatment modality for cancer, including when surgery is appropriate, types of surgical procedures, and the role of surgery in cancer cure and palliation. Our guest is Dr. Elliott Arko-Boham who is a Plastic Surgeon at the Korle-Bu Teaching Hospital.

The following article of the Health industry is: “Companion Diagnostics: The Key to Precision Cancer Therapy” by Jorge Melendez Zajgla, General Director, Instituto Nacional de Medicina Genómica.

Dr. Jonathan Sessler, Professor of Chemistry at The University of Texas at Austin, is no stranger to taking an active role in directing his own path. Being a three-time Hodgkin's Lymphoma cancer survivor, Dr. Sessler's battle with cancer inspired him to research porphyrins, a class of pigments which are essential for biological processes like oxygen transport. On this exciting episode of Let's Talk Chemistry edited by Jasmine Winter, hosts Neel Youts and Jason Lu discuss our interview with Dr. Jonathan Sessler, from unique upbringing growing up in a family of scientists to his pioneering work on creating expanded porphyrins called texaphyrins and co-founding Pharmacyclics, a successful biopharmaceutical company primarily focused on the development of cancer therapies. We hope you enjoy!

Featuring an interview with Dr Neel Pasricha, including the following topics: Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00) Association of corneal toxicities with ADCs (4:56) Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02) Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44) Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55) Other ocular toxicities associated with cancer therapies (24:26) Prevention and management of corneal toxicity (33:58) Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39) General clinical pearls on the management of ocular toxicities with cancer therapies (48:04) CME information and select publications

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.

Featuring perspectives from Prof Rebecca A Dent, Dr Hans Lee, Dr Neel Pasricha and Dr Tiffany A Richards, including the following topics:  Introduction: The Patient Experience (0:00) Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Dr Pasricha (10:28) Ocular Toxicities in Multiple Myeloma (45:33) Ocular Toxicities in Breast Cancer (50:34) CME information and select publications

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.

This week on our Live Show we discussed Trump Tarriffs illegal, Nato fotress in Romania, arson firefighter, ebbing asylum hotel, health and more   Donations https://www.awakeningpodcast.org/support/   #awakening #brainfitness #Romania   About my Co-Host: Arnold Beekes Innovator, certified coach & trainer and generalist. First 20 years in technology and organizational leadership, then 20 years in psychology and personal leadership (all are crucial for innovation).   What we Discussed:   00:26 What the Picture on our Introduction Means   01:15 What we will be discussing in this weeks Show 03:00 LeeuWarden Update 05:20 Why Courts Can Not be Trusted 06:30 How you can Help the Podcast 07:25 Trumps Tariffs are Illegal 10:10 Is the US a Dictatorship 12:20 NATO Building its Largest Military Base in Romania    14:30 Arsonist was a Firefighter 17:24 Shariah law recognised in Austria 19:12 The dangers of the Burka 20:05 Epping Asylum Hotel Cout Case Overturned 25:20 Are You Working on Brain Fitness 26:45 Google New Phone Pixel 10 30:40 Googles Jules 2.0 32:30 ChatGpt Court case for causing Suicide 36:40 Denmark make your Face and Voice as your IP 39:17 How a Virtual Assistant Can Help your Business 40:00 Cancer Therapy for Cat might help Humans 41:25 From Fishing and Oil Disaster to Farming 43:50 Spirecord Repair 46:00 Universal Health Trackers 48:05 The dangers of Devices that use WiFi 48:45 Organipeel has been discontinued 51:25 More than 2 Billion lack access to Safe Drinking Water 56:35 Pure Human by Greg Braden 58:00 Mecico's Massive Poverty Reduction 1:00:40 Flight Pattern of Birds   How to Contact Arnold Beekes:   https://braingym.fitness/   https://www.linkedin.com/in/arnoldbeekes/   Donations ⁠⁠ https://www.awakeningpodcast.org/support/   https://www.podpage.com/speaking-podcast/support/ ⁠⁠   All about Roy / Brain Gym & Virtual Assistants at https://roycoughlan.com/  

This week on our Live Show we discussed Trump Tarriffs illegal, Nato fotress in Romania, arson firefighter, ebbing asylum hotel, health and more Donations https://www.awakeningpodcast.org/support/ #awakening #brainfitness #Romania About my Co-Host:Arnold Beekes Innovator, certified coach & trainer and generalist. First 20 years in technology and organizational leadership, then 20 years in psychology and personal leadership (all are crucial for innovation). What we Discussed: 00:26 What the Picture on our Introduction Means 01:15 What we will be discussing in this weeks Show03:00 LeeuWarden Update05:20 Why Courts Can Not be Trusted06:30 How you can Help the Podcast07:25 Trumps Tariffs are Illegal10:10 Is the US a Dictatorship12:20 NATO Building its Largest Military Base in Romania  14:30 Arsonist was a Firefighter17:24 Shariah law recognised in Austria19:12 The dangers of the Burka20:05 Epping Asylum Hotel Cout Case Overturned25:20 Are You Working on Brain Fitness26:45 Google New Phone Pixel 1030:40 Googles Jules 2.032:30 ChatGpt Court case for causing Suicide36:40 Denmark make your Face and Voice as your IP39:17 How a Virtual Assistant Can Help your Business40:00 Cancer Therapy for Cat might help Humans41:25 From Fishing and Oil Disaster to Farming43:50 Spirecord Repair46:00 Universal Health Trackers48:05 The dangers of Devices that use WiFi48:45 Organipeel has been discontinued51:25 More than 2 Billion lack access to Safe Drinking Water56:35 Pure Human by Greg Braden58:00 Mecico's Massive Poverty Reduction1:00:40 Flight Pattern of Birds How to Contact Arnold Beekes: https://braingym.fitness/ https://www.linkedin.com/in/arnoldbeekes/ Donations ⁠⁠ https://www.awakeningpodcast.org/support/ https://www.podpage.com/speaking-podcast/support/ ⁠⁠ All about Roy / Brain Gym & Virtual Assistants athttps://roycoughlan.com/ 

Could cancer treatment be approached in a way that restores the body instead of breaking it down? In this powerful conversation, Dr. Hotze sits down with Dr. Nathan Goodyear, a leader in integrative oncology, to discuss how addressing the root causes of cancer can help patients achieve better health outcomes and an improved quality of life. Dr. Goodyear explains how his approach focuses on supporting the immune system, reducing inflammation, and using natural, targeted therapies that work with the body's healing processes. They explore how factors like the immune system, nutrition, toxins, tubal ligation, hysterectomy, mitochondria, and hormone imbalances play a role in overall impacts on your health, unnecessary symptoms, and even the potential development of cancer, and how restoring balance can help assist the body's ability to fight back in resolving symptoms and illnesses. If you or someone you love is facing cancer, this episode will open your eyes to treatment strategies that prioritize health, wellness, and quality of life over the one-size-fits-all approach of conventional medicine. For more information about Dr. Goodyear and other resources discussed today, please visit the following.   @ Dr.Goodyear (Instagram) https://www.instagram.com/dr.goodyear/?hl=en Website URLs: https://williamscancerinstitute.com/ https://pre-scribed.com/ https://www.off-scriptrx.com/ https://www.docgoodyear.com/ https://metabolicregen.com/   Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

In this episode: EMPOWER-SMS GP helps bridge the gap in post treatment support Reinforces medication adherence, especially for endocrine therapy Encourages achievable lifestyle changes that align with healthcare professionals’ goals Easy to implement with minimal healthcare professionals or admin workload Strengthens primary care’s role in survivorship and chronic care Host: Dr Rebecca Overton | Total Time:34 mins Experts: Dr Anna Singelton, Senior Research Fellow; Prof Elisabeh Elder, Specialist Breast Surgeon; A/Prof Carolyn Ee, Academic General Practitioner; Robyn Kelly, High school teacher Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

CME credits: 0.50 Valid until: 17-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/ This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety across hormone receptor–positive and triple-negative disease settings. The discussion contrasts molecular structures, dosing schedules, and toxicity profiles of each ADC, providing insight into their positioning in treatment algorithms. Practical strategies for therapy sequencing, patient selection, and shared decision-making are emphasized throughout.=

CME credits: 0.50 Valid until: 17-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/ This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety across hormone receptor–positive and triple-negative disease settings. The discussion contrasts molecular structures, dosing schedules, and toxicity profiles of each ADC, providing insight into their positioning in treatment algorithms. Practical strategies for therapy sequencing, patient selection, and shared decision-making are emphasized throughout.=

Dr. Abe Delpassand, Founder, CEO, and Chairman of the Board at RadioMedix, is concentrated on the development of radiopharmaceuticals for cancer diagnosis and treatment. Advancements in handling radioactive materials and increased availability have enabled the growth of the use of alpha-emitting and beta-emitting radioisotopes in treating cancers that have been resistant to other therapies. Alpha-emitting radioisotopes are particularly interesting because they can cause double-strand DNA damage in cancer cells, making the probability of cancer recurrence much less likely. Abe explains, "Just a brief introduction related to what radiopharmaceuticals are. These are drugs that have three parts, basically. One part is the radioactive material. The second part is what we call a ligand. It's like a vehicle that takes the radioactive material to the target that we have. And there is a third component, which is like a chain attaching the radioisotope to the ligand. Radiopharmaceuticals qualify as a form of therapy because we target a specific receptor antigen metabolic pathway in cancer cells, and this is how we can reach the cancer cells. It has two components: one, diagnostic and therapeutic, which is very unique to this modality because in many other cancer therapies before the treatment, we don't have any way to make sure that the patient who is receiving the treatment, that actually the drug can reach the cancer the patient has." "We have been talking about the value of alpha-emitters in delivering high level of radiation in a targeted fashion to the cancer cells, but we in the last, I'd say 10 years or more, we have learned how to handle these isotopes. That's one aspect of the science part. The other aspect is the availability of these isotopes. Now the supply of these isotopes is becoming a lot more, and they are becoming more available."    #RadioMedix #TeamRadioMedix #Radiopharmaceuticals #TargetedAlphaTherapy #OncologyInnovation #NuclearMedicine #CancerResearch #RadiogandTherapy #PrecisionOncology #Theranostics #SPICACenter #OncologyCommunity #AlphaEmittingRadioisotopes #BetaEmittingRadioisotopes radiomedix.com Download the transcript here

Dr. Abe Delpassand, Founder, CEO, and Chairman of the Board at RadioMedix, is concentrated on the development of radiopharmaceuticals for cancer diagnosis and treatment. Advancements in handling radioactive materials and increased availability have enabled the growth of the use of alpha-emitting and beta-emitting radioisotopes in treating cancers that have been resistant to other therapies. Alpha-emitting radioisotopes are particularly interesting because they can cause double-strand DNA damage in cancer cells, making the probability of cancer recurrence much less likely. Abe explains, "Just a brief introduction related to what radiopharmaceuticals are. These are drugs that have three parts, basically. One part is the radioactive material. The second part is what we call a ligand. It's like a vehicle that takes the radioactive material to the target that we have. And there is a third component, which is like a chain attaching the radioisotope to the ligand. Radiopharmaceuticals qualify as a form of therapy because we target a specific receptor antigen metabolic pathway in cancer cells, and this is how we can reach the cancer cells. It has two components: one, diagnostic and therapeutic, which is very unique to this modality because in many other cancer therapies before the treatment, we don't have any way to make sure that the patient who is receiving the treatment, that actually the drug can reach the cancer the patient has." "We have been talking about the value of alpha-emitters in delivering high level of radiation in a targeted fashion to the cancer cells, but we in the last, I'd say 10 years or more, we have learned how to handle these isotopes. That's one aspect of the science part. The other aspect is the availability of these isotopes. Now the supply of these isotopes is becoming a lot more, and they are becoming more available."    #RadioMedix #TeamRadioMedix #Radiopharmaceuticals #TargetedAlphaTherapy #OncologyInnovation #NuclearMedicine #CancerResearch #RadiogandTherapy #PrecisionOncology #Theranostics #SPICACenter #OncologyCommunity #AlphaEmittingRadioisotopes #BetaEmittingRadioisotopes radiomedix.com Listen to the podcast here

The wealth of bacteria resident on and in your body may have much to do with your overall health, including how you respond to different therapies for cancer. Johns Hopkins Kimmel Cancer Center director William Nelson explains views from a … Your gut microbiome may have much to do with how you respond to cancer therapy, Elizabeth Tracey reports Read More »

This episode discusses findings from a recent systematic review preprint, examining how the embryonic germ layer origin of various cancers may relate to differences in therapy response. Drawing on evidence from clinical trials and mechanistic studies, we explore patterns observed among mesoderm-, endoderm-, and ectoderm-derived tumors.The conversation highlights how integrating developmental biology concepts into oncology may help inform treatment decisions and research design. This episode is intended for students, researchers, and clinicians interested in cancer biology, translational research, and personalized medicine.Please note: The views of this podcast represent those of my guest and I, and do not constitute medical advice, recommendations or consultations. Please see a state certified and board certified professional for medical, advice and recommendations. We disclaim any loss in any way.Link to Preprint: Embryonic Germ Layer Origin as a Potential Determinant of Cancer Therapy Response: A Systematic Review and Meta-Analysis of Contemporary Evidence | medRxivNote: Some of this episode's production involved the use of AI.

This year's Randy Shaver Cancer Research and Community Fund's Angel Award recipient talks about his cutting edge work with Natural Killer Cell immunotherapy, CAR-T cell immunotherapy and the future of genome engineering in new therapies for treating cancer.Here how he became interested in creating new ways to look at knocking down cancer, his background as a youth growing up in rural Minnesota and trending as one of the most talked about researchers at the University of MN.

BUFFALO, NY - May 23, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma." The study, led by first authors Leonardo Gomes da Fonseca from Hospital das Clínicas, Universidade de São Paulo, Brazil, and Federico Piñero from Hospital Universitario Austral, Argentina, investigated how patients with advanced liver cancer in Latin America respond to a widely used immunotherapy combination. The researchers found that although a minority of patients developed immune-related side effects, these events did not significantly impact overall survival. Their findings highlight the importance of early recognition and careful management of such side effects in real-world clinical settings. Liver cancer is a leading cause of cancer deaths worldwide, with limited treatment options for patients diagnosed at an advanced stage. Immunotherapy, particularly the combination of atezolizumab and bevacizumab, has become a standard approach. However, these treatments can sometimes trigger the body's immune system to attack healthy organs, leading to what are called immune-related adverse events, or irAEs. Until now, little data existed on how frequently these events occur in Latin American patients and whether they impact treatment outcomes. The researchers followed 99 patients from Argentina, Brazil, Chile, and Colombia, most of whom had cirrhosis or underlying liver disease. They received atezolizumab and bevacizumab for a median duration of six months. The researchers reported that only 18% of the patients experienced immune-related side effects, most commonly affecting the liver (hepatitis) and thyroid (thyroiditis). Most of these cases were mild or moderate, and half of them resolved completely within a month. Only eight patients needed treatment with steroids to control the immune response. Importantly, the occurrence of immune-related side effects did not affect how long patients survived after starting treatment. The median survival was the same—18.5 months—for both those who experienced irAEs and those who did not. This result suggests that while irAEs require careful management, they may not reduce the overall benefits of immunotherapy. Another significant finding was that patients with higher levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, were more likely to experience these side effects. This information could help clinicians identify patients who need closer control during treatment. “Notably, baseline alpha-fetoprotein (AFP) values ≥400 ng/ml were significantly associated with the development of irAEs.” The study also points to key differences between clinical trial results and real-world experiences. While clinical trials report higher rates of side effects, this real-world data showed a lower incidence, possibly due to less intensive monitoring or differences in how side effects are documented in everyday practice. In summary, this study highlights that patients require ongoing vigilance and individualized care when treating liver cancer with immunotherapy. It provides valuable information to healthcare providers in Latin America and other regions with similar patient populations, aiming to improve outcomes while minimizing risks. DOI - https://doi.org/10.18632/oncotarget.28721 Correspondence to - Federico Piñero - fpinerof@cas.austral.edu.ar To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

- Green Tea and Cognitive Benefits (0:10) - Critique of Pharmaceuticals and Big Pharma (2:39) - Green Tea and Brain Health (4:31) - Speed Cubing and Cognitive Training (10:47) - Green Tea and Cancer Prevention (15:59) - Green Tea and Heavy Metal Detoxification (24:45) - L-Theanine and Anxiety Relief (30:04) - Catechins and Polyphenols in Green Tea (36:21) - Green Tea Extracts and Supplements (39:14) - Green Tea and Cancer Therapy (50:57) - Colloidal Silver and Its Benefits (1:11:38) - Silver Nanoparticles and Cancer Research (1:23:02) - Historical and Metaphysical Significance of Metals (1:26:08) - Economic and Political Implications of Metals (1:27:53) - Challenges and Opportunities in Health and Science (1:30:08) - Personal Reflections and Future Plans (1:37:17) - Final Thoughts and Gratitude (1:41:15) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

A new study from the Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, published in Oncotarget, reveals that the gene p53, long known as the “guardian of the genome,” may be even more powerful than previously thought. By studying it in non-cancerous human cells, researchers discovered how p53 stops risky cell growth and uncovered two new potential targets for cancer therapy. Understanding p53: The Genome's Guardian Against Cancer The p53 gene is one of the most important natural defenses our body has against cancer. When functioning properly, p53 detects damage in a cell's DNA and either stops the cell from dividing or pushes it to self-destruct. This process helps prevent potentially dangerous mutations from spreading. However, many cancers find ways to silence or mutate p53, allowing uncontrolled growth and resistance to treatments. Studying p53 in a clear and accurate way has long been a challenge. Most cancer cell models used in research already carry numerous genetic mutations, which can mask or alter how p53 truly functions. To fully understand this vital tumor-suppressing gene, scientists needed a model that closely resembled healthy, genetically stable human cells—yet could still be maintained and studied over time in the laboratory. The Study: Exploring p53 in Normal and Cancer Cell Models Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz explored p53 activity using a uniquely suitable cell line: hTERT-RPE1. These non-cancerous human cells are immortalized using telomerase, meaning they continue dividing like cancer cells, but without the chaotic mutations seen in tumors. This makes them an excellent model for studying how p53 operates in near-normal conditions. Full blog - https://www.oncotarget.org/2025/04/22/new-insights-into-p53-a-powerful-genes-role-in-cancer-therapy/ Paper DOI - https://doi.org/10.18632/oncotarget.28690 Correspondence to - Fred Bunz - fredbunz@jhmi.edu Video short - https://www.youtube.com/watch?v=Psxj3ctbTuk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28690 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, p53, ionizing radiation, immortalized cells, ALDH3A1, NECTIN4 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode, host Jonathan Sackier speaks with Alexander Spira about cutting-edge advances in lung and colorectal cancer, including EGFR and KRAS-targeted therapies. They also discuss Spira's leadership in oncology research, his thoughts on the evolving ‘town-gown' dynamic in US medicine, and his hopes for the future of cancer care.  Timestamps:  00:00 – Introduction 01:50 – Most memorable family travel adventure 03:30 – What inspired you to go into oncology 05:49 – Three recent publications in lung cancer 07:02 – Real-world data on colorectal cancer 08:15 – Sex/gender differences in non-small cell lung cancer 11:53 – The science of KRAS mutations and drug development 15:07 – Accelerating diagnostics and access to therapies 17:13 – The ‘town-gown' debate in American healthcare 18:09- Three Wishes 

Episode Summary: Why is cancer on the rise—especially among younger generations?  In this powerful episode of The Art of Living Well Podcast, we sit down with Dr. Tony Jimenez to discuss the root causes of cancer, the role of integrative oncology, and his seven key principles for cancer therapy. Dr. Tony shares his personal journey into holistic cancer care, highlighting the importance of nutrition, detoxification, immune support, and emotional healing.  He also breaks down non-toxic treatments, the significance of dental health, and why practices like coffee enemas and oxygenation can make a profound impact on overall wellness. If you're looking to take proactive steps toward cancer prevention, boost your health, and gain insights into holistic healing, this episode is a must-listen!   Key Takeaways: ✅ Toxicity & lifestyle choices play a major role in cancer development  ✅ A personalized approach to nutrition is key to healing & longevity  ✅ Detoxification & immune system support are crucial for disease prevention  ✅ Coffee enemas can enhance cognitive function & boost glutathione levels  ✅ Oxygenation is essential for overall health—and it's free!  ✅ Your oral microbiome & dental health directly impact your body's wellness  ✅ Emotional healing & trauma work are vital for long-term health Tune in now to learn how you can take charge of your health and longevity! Chapters 08:26 Understanding Cancer: Causes and Growth 19:47 Trends in Cancer: What We're Seeing Today 20:16 The Seven Key Principles of Cancer Therapy 34:05 The Power of Coffee Enemas 38:38 Understanding the Microbiome 41:27 Dental Health and Toxicity 53:00 The Emotional Component of Healing 01:00:10 Practical Steps for Longevity We'd love to hear your thoughts! Connect with us on social media or email us at theartoflivingwellpodcast@gmail.com

Dr. Antonio Jimenez discusses the innovative treatments and holistic approach at Hope4Cancer Treatment Centers. Learn about the comprehensive strategies used to combat cancer and support healing. #CancerTreatment #HolisticHealth #Hope4Cancer

Big Pharma, Big Tech, and the Deep State don't want you to hear this conversation, but Dr. Pierre Kory and I expose their lies anyway. The war on medicine is real—COVID was just the beginning. Now they're rolling out mRNA tech for cancer, embedding AI in biotech, and pushing a transhumanist agenda that turns humans into lab rats. What's worse? They're gaslighting us, poisoning our food, manipulating our health, and calling it “science.” We break down why RFK Jr. is the man to finally dismantle this corrupt system, the lies behind the cancer industry, and why so many people are sick, infertile, and dying young. This is the medical-industrial complex's worst nightmare.Dr Pierre Kory and Jeff Dornik will both be speaking at the upcoming Summit for Truth & Wellness in Rochester, NY, on March 29th, alongside Mary Holland, Naomi Wolf, Dr Mary Talley Bowden and Shannon Joy. Get your tickets at https://summitfortruth.com.Follow Dr Pierre Kory on X: https://x.com/PierreKoryFollow Jeff Dornik on Pickax: https://pickax.com/jeffdornikFollow Maverick Broadcasting on Pickax: https://pickax.com/maverickbroadcastingPrepare for the next pandemic with the Contagion Emergency Kit from The Wellness Company, offering life-saving medications like Ivermectin, Hydroxychloroquine, Azithromycin, Oseltamivir, and Budesonide. Use code JEFF for 10% off and ensure you have the necessary tools and guidance at the ready. https://twc.health/jeff

Dermatologic toxicities associated with oncology treatment can significantly impact quality of life and treatment adherence for patients with breast cancer. The Association of Cancer Care Centers (ACCC) is committed to providing up-to-date guidance on managing these dermatologic side effects to enhance clinical outcomes. In this episode of CANCER BUZZ, Allison Gordon, MD, a supportive oncodermatologist at Memorial Sloan Kettering Cancer Center, discusses the dermatologic toxicities associated with breast cancer treatment. Dr Gordon explores preventive measures that oncologists can implement early in the treatment course and offers alternative resources for oncology clinicians when an oncodermatologist referral is not feasible. Additionally, she highlights capivasertib, a recently approved antineoplastic drug, and reviews its associated cutaneous adverse events, along with supportive care and management strategies. Thank you to AstraZeneca for their support of this program.   Allison Gordon, MD Dermatologist Memorial Sloan Kettering Cancer Center New York, NY   “Because many of these medications can cause dry skin, which can be debilitating for patients... [we recommend] using a thick ointment or cream moisturizer on their damp skin after they shower... it doesn't have to be anything expensive... I always recommend that to all patients regardless of what treatment they're on.”– Allison Gordon, MD    Additional Reading/Sources  ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies education program (https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/dermatologic-toxicities?)   Targeted Therapy Side Effects – American Cancer Society  (https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/side-effects.html)   Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569770/)   Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy (https://ascopubs.org/doi/10.1200/EDBK_289911)   Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatolgy Study Group (https://mascc.org/resources/mascc-guidelines/)   Guidelines for the Prevention and Treatment of Radiation-Induced Skin Reactions (https://mascc.org/resources/mascc-guidelines/)   Guidelines for Prevention and Management of Dermatological Toxicities Related to Anticancer Agents (https://pubmed.ncbi.nlm.nih.gov/33248228/)

Cancer rates are at an all-time high...     And while conventional treatments continue to advance, there are natural therapies being widely used in other parts of the world that remain underutilized in the United States.     One such therapy is mistletoe extract, a plant-based treatment that has been shown to support immune function and improve quality of life in cancer patients.      So on today's Cabral Concept 3315, I want to dive into the latest research on mistletoe therapy, its potential benefits, and what the science really says about its role in integrative cancer care. Enjoy the show, and let me know your thoughts!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3315 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

John Richardson, Founder & Chief Visionary Officer of Operation World Without Cancer and Founder of Richardson Nutritional Center, passionately shares his family's advocacy for Laetrile, a natural cancer treatment derived from apricot seeds, and recounts powerful success stories in its application. The episode provokes critical questions about the mainstream medical approach to cancer and encourages listeners to explore natural remedies as essential health strategies. • The origins of John's family's journey in cancer treatment • Fundamental chemistry of amygdalin within apricot seeds • Case study of little Shane Horton's dramatic recovery • The importance of nutrition in prevention and combatting cancer • Challenges faced by alternative treatments in a pharmaceutical-dominant environment • Launching Operation World Without Cancer to consolidate natural treatment strategies • Call to action: Explore a holistic approach to health and wellnessLearn more about John and his mission.Shop apricot seeds or Laetrile products and save with this HealingStrong discount. Automatically applied. HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please consider supporting our mission by becoming a part of our Membership Program, as a monthly donor.When you do, you will receive additional resources such as: webinars, access to ALL our past and most recent conference videos, downloadables and more, as a bonus.To learn more, head to the HealingStrong Membership Program link below: Membership Program

When it comes to supporting the body's natural detox and healing processes, the lymphatic system is often an unsung hero. As Founder and CEO of Medella Health, Desiree De Spong created Flowpresso, a 3-in-1 therapy combining compression, heat, and deep pressure to enhance lymphatic flow and detoxification. In our conversation, Desiree shares practical strategies for optimizing lymphatic health and how regular lymphatic drainage can lead to profound health benefits. She highlights the importance of supporting the detoxification and elimination pathways, and signs your body needs cleansing and purifying. Finally, Desiree details the creation and benefits of the innovative Flowpresso technology and its at-home tools so you can regularly give your lymphatic system the attention and care it deserves.DISCLAIMER: This podcast is for educational purposes only and not intended for diagnosing or treating illnesses. The hosts disclaim responsibility for any adverse effects from using the information presented. Consult your healthcare provider before using referenced products. This podcast may include paid endorsements.THIS SHOW IS BROUGHT TO YOU BY:SOLTEC | Visit lukestorey.com/soltec and use code LUKE2024 to get the best available discount on your Soltec Health System.MAGNESIUM BREAKTHROUGH | Use code LUKE10 for 10% off at bioptimizers.com/luke.LEELA QUANTUM TECH. | Go to lukestorey.com/leelaq and use the code LUKE10 for 10% off their product line.BON CHARGE | Use the code LIFESTYLIST for 15% off at boncharge.com/lifestylistMORE ABOUT THIS EPISODE:(00:00:00) Introduction(00:00:08) Healing Trauma Through Activating the Lymphatic System(00:09:23) Lymphatic Basics(00:19:25) Cancer Therapies & Safe Practices for Vibration Plates & Dry Brushing(00:36:48) The Four Pathways of Elimination(00:58:17) Changing Stress, Anxiety, & Sleep with Flowpresso(01:21:57) Finding a Practitioner & Optimizing Your Treatment (01:29:26) Flow at Home Portable ToolsResources:• Website: flowpressousa.com (Use code LUKE for $10 off Flow Orb and Flow Vibrate and $555 off Flowpresso)• Instagram: @flowpresso_intThe Life Stylist is produced by Crate Media.

Here are the show notes for The James Altucher Show episode featuring Naveen Jain:A Note from James:“Oh my gosh. What a podcast with Naveen Jain. I first had Naveen on in 2014 or 2015, and he remembered it perfectly. That conversation was so fun, I still remember it like it was yesterday. It's crazy because I've done over 1,500 episodes, but that one stuck with me.Back then, we talked about Moon Express and his journey building rockets to the moon. Now, almost ten years later, Naveen has built several other companies, including Viome, which uses cutting-edge technology to analyze your microbiome and help people live longer healthier lives. Today, we're talking about his new book, The Youth Formula: Outsmart Your Genes and Unlock the Secrets to Longevity.At first, I'll admit, I was tired of hearing about longevity—everyone seems to be saying the same thing—but Naveen has such a unique take on it. We got into everything: from the role of microbes in our health to fecal transplants (yes, really) and how bacteria can influence personality traits. It was fascinating. We even talked about how changing your microbiome could literally alter your personality.There's so much in this episode that it's going to blow your mind. I hope it's not another ten years before we get Naveen back on the show. I'm definitely going to take him up on some of his suggestions, and maybe I'll have some results to share in a few months. Here's Naveen Jain.”Episode Description:In this episode, James Altucher is joined by serial entrepreneur Naveen Jain to explore the cutting-edge science of longevity, gut health, and human potential. Naveen, the founder of Viome and author of The Youth Formula, dives deep into how the microbiome shapes our health and even our personality. He explains why genes aren't destiny, how microbes may play a more important role in our health than DNA, and what steps we can take to live longer healthier lives. James and Naveen also discuss the surprising science behind fecal transplants, the future of personalized nutrition, and why finding purpose might be the ultimate key to longevity.What You'll Learn:How the microbiome plays a crucial role in your overall health—and might even affect your personality.Why DNA isn't as important as you think when it comes to disease and longevity.The latest research on fecal transplants and their impact on treating various diseases.How personalized nutrition can help you optimize your health based on your unique biology.The connection between purpose, community, and living a longer life.Timestamped Chapters:[01:30] Introduction: Reconnecting with Naveen Jain after 10 years[02:44] The Youth Formula and Viome: Outsmarting your genes[03:17] Microbiome's role in health: 99.999% of your body is microbes[04:02] Fecal transplants and personality: Can you inherit personality traits?[06:00] Personalized nutrition: Why “healthy” food isn't healthy for everyone[12:00] The power of purpose: Why having a reason to live is crucial for longevity[21:32] Changing the microbiome to treat disease: Fecal transplants and immunotherapy[29:24] How microbiomes affect mental health: Serotonin and gut-brain connections[39:51] The role of AI in personalized health recommendations at Viome[46:00] Stress and the sympathetic/parasympathetic modes: Modern stressors vs. ancient survival instincts[48:01] The role of exercise: Why 30-45 minutes of movement is enough[49:00] Sleep and health: The importance of quality over quantity[56:58] Entrepreneurial insights: Why a smooth life isn't what you want as an entrepreneur[58:07] Long-term vision: How Viome is focused on extending life by improving microbiome health[65:00] Wrap-up: James's thoughts on the future of health and Naveen's closing remarksAdditional Resources:The Youth Formula: Outsmart Your Genes and Unlock the Secret to LongevityViome: Learn more about personalized nutrition and microbiome analysis.Naveen Jain's Official Website ------------What do YOU think of the show? Head to JamesAltucherShow.com/listeners and fill out a short survey that will help us better tailor the podcast to our audience!Are you interested in getting direct answers from James about your question on a podcast? Go to JamesAltucherShow.com/AskAltucher and send in your questions to be answered on the air!------------Visit Notepd.com to read our idea lists & sign up to create your own!My new book, Skip the Line, is out! Make sure you get a copy wherever books are sold!Join the You Should Run for President 2.0 Facebook Group, where we discuss why you should run for President.I write about all my podcasts! Check out the full post and learn what I learned at jamesaltuchershow.com------------Thank you so much for listening! If you like this episode, please rate, review, and subscribe to “The James Altucher Show” wherever you get your podcasts: Apple PodcastsiHeart RadioSpotifyFollow me on social media:YouTubeTwitterFacebookLinkedIn